Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats

Anette M. Kunig, Vivek Balasubramaniam, Neil E. Markham, Danielle Morgan, Gregory Montgomery, Theresa R. Grover, Steven H. Abman

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

VEGF signaling inhibition decreases alveolar and vessel growth in the developing lung, suggesting that impaired VEGF signaling may contribute to decreased lung growth in bronchopulmonary dysplasia (BPD). Whether VEGF treatment improves lung structure in experimental models of BPD is unknown. The objective was to determine whether VEGF treatment enhances alveolarization in infant rats after hyperoxia. Two-day-old Sprague-Dawley rats were placed into hyperoxia or room air (RA) for 12 days. At 14 days, rats received daily treatment with rhVEGF-165 or saline. On day 22, rats were killed. Tissue was collected. Morphometrics was assessed by radial alveolar counts (RAC), mean linear intercepts (MLI), and skeletonization. Compared with RA controls, hyperoxia decreased RAC (6.1 ± 0.4 vs. 11.3 ± 0.4, P <0.0001), increased MLI (59.2 ± 1.8 vs. 44.0 ± 0.8, P <0.0001), decreased nodal point density (447 ± 14 vs. 503 ± 12, P <0.0004), and decreased vessel density (11.7 ± 0.3 vs. 18.9 ± 0.3, P <0.001), which persisted despite RA recovery. Compared with hyperoxic controls, rhVEGF treatment after hyperoxia increased RAC (11.8 ± 0.5, P <0.0001), decreased MLI (42.2 ± 1.2, P <0.0001), increased nodal point density (502 ± 7, P <0.0005), and increased vessel density (23.2 ± 0.4, P <0.001). Exposure of neonatal rats to hyperoxia impairs alveolarization and vessel density, which persists despite RA recovery. rhVEGF treatment during recovery enhanced vessel growth and alveolarization. We speculate that lung structure abnormalities after hyperoxia may be partly due to impaired VEGF signaling.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume289
Issue number4 33-4
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Hyperoxia
Lung Injury
Vascular Endothelial Growth Factor A
Air
Recovery Room
Bronchopulmonary Dysplasia
Lung
Therapeutics
Growth
Sprague Dawley Rats
Theoretical Models

Keywords

  • Angiogenesis
  • Bronchopulmonary dysplasia
  • Lung development
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cell Biology
  • Physiology

Cite this

Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. / Kunig, Anette M.; Balasubramaniam, Vivek; Markham, Neil E.; Morgan, Danielle; Montgomery, Gregory; Grover, Theresa R.; Abman, Steven H.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 289, No. 4 33-4, 10.2005.

Research output: Contribution to journalArticle

Kunig, Anette M. ; Balasubramaniam, Vivek ; Markham, Neil E. ; Morgan, Danielle ; Montgomery, Gregory ; Grover, Theresa R. ; Abman, Steven H. / Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2005 ; Vol. 289, No. 4 33-4.
@article{ee203a87063e453384d15c8fd4cb870c,
title = "Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats",
abstract = "VEGF signaling inhibition decreases alveolar and vessel growth in the developing lung, suggesting that impaired VEGF signaling may contribute to decreased lung growth in bronchopulmonary dysplasia (BPD). Whether VEGF treatment improves lung structure in experimental models of BPD is unknown. The objective was to determine whether VEGF treatment enhances alveolarization in infant rats after hyperoxia. Two-day-old Sprague-Dawley rats were placed into hyperoxia or room air (RA) for 12 days. At 14 days, rats received daily treatment with rhVEGF-165 or saline. On day 22, rats were killed. Tissue was collected. Morphometrics was assessed by radial alveolar counts (RAC), mean linear intercepts (MLI), and skeletonization. Compared with RA controls, hyperoxia decreased RAC (6.1 ± 0.4 vs. 11.3 ± 0.4, P <0.0001), increased MLI (59.2 ± 1.8 vs. 44.0 ± 0.8, P <0.0001), decreased nodal point density (447 ± 14 vs. 503 ± 12, P <0.0004), and decreased vessel density (11.7 ± 0.3 vs. 18.9 ± 0.3, P <0.001), which persisted despite RA recovery. Compared with hyperoxic controls, rhVEGF treatment after hyperoxia increased RAC (11.8 ± 0.5, P <0.0001), decreased MLI (42.2 ± 1.2, P <0.0001), increased nodal point density (502 ± 7, P <0.0005), and increased vessel density (23.2 ± 0.4, P <0.001). Exposure of neonatal rats to hyperoxia impairs alveolarization and vessel density, which persists despite RA recovery. rhVEGF treatment during recovery enhanced vessel growth and alveolarization. We speculate that lung structure abnormalities after hyperoxia may be partly due to impaired VEGF signaling.",
keywords = "Angiogenesis, Bronchopulmonary dysplasia, Lung development, Vascular endothelial growth factor",
author = "Kunig, {Anette M.} and Vivek Balasubramaniam and Markham, {Neil E.} and Danielle Morgan and Gregory Montgomery and Grover, {Theresa R.} and Abman, {Steven H.}",
year = "2005",
month = "10",
doi = "10.1152/ajplung.00336.2004",
language = "English (US)",
volume = "289",
journal = "American Journal of Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "4 33-4",

}

TY - JOUR

T1 - Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats

AU - Kunig, Anette M.

AU - Balasubramaniam, Vivek

AU - Markham, Neil E.

AU - Morgan, Danielle

AU - Montgomery, Gregory

AU - Grover, Theresa R.

AU - Abman, Steven H.

PY - 2005/10

Y1 - 2005/10

N2 - VEGF signaling inhibition decreases alveolar and vessel growth in the developing lung, suggesting that impaired VEGF signaling may contribute to decreased lung growth in bronchopulmonary dysplasia (BPD). Whether VEGF treatment improves lung structure in experimental models of BPD is unknown. The objective was to determine whether VEGF treatment enhances alveolarization in infant rats after hyperoxia. Two-day-old Sprague-Dawley rats were placed into hyperoxia or room air (RA) for 12 days. At 14 days, rats received daily treatment with rhVEGF-165 or saline. On day 22, rats were killed. Tissue was collected. Morphometrics was assessed by radial alveolar counts (RAC), mean linear intercepts (MLI), and skeletonization. Compared with RA controls, hyperoxia decreased RAC (6.1 ± 0.4 vs. 11.3 ± 0.4, P <0.0001), increased MLI (59.2 ± 1.8 vs. 44.0 ± 0.8, P <0.0001), decreased nodal point density (447 ± 14 vs. 503 ± 12, P <0.0004), and decreased vessel density (11.7 ± 0.3 vs. 18.9 ± 0.3, P <0.001), which persisted despite RA recovery. Compared with hyperoxic controls, rhVEGF treatment after hyperoxia increased RAC (11.8 ± 0.5, P <0.0001), decreased MLI (42.2 ± 1.2, P <0.0001), increased nodal point density (502 ± 7, P <0.0005), and increased vessel density (23.2 ± 0.4, P <0.001). Exposure of neonatal rats to hyperoxia impairs alveolarization and vessel density, which persists despite RA recovery. rhVEGF treatment during recovery enhanced vessel growth and alveolarization. We speculate that lung structure abnormalities after hyperoxia may be partly due to impaired VEGF signaling.

AB - VEGF signaling inhibition decreases alveolar and vessel growth in the developing lung, suggesting that impaired VEGF signaling may contribute to decreased lung growth in bronchopulmonary dysplasia (BPD). Whether VEGF treatment improves lung structure in experimental models of BPD is unknown. The objective was to determine whether VEGF treatment enhances alveolarization in infant rats after hyperoxia. Two-day-old Sprague-Dawley rats were placed into hyperoxia or room air (RA) for 12 days. At 14 days, rats received daily treatment with rhVEGF-165 or saline. On day 22, rats were killed. Tissue was collected. Morphometrics was assessed by radial alveolar counts (RAC), mean linear intercepts (MLI), and skeletonization. Compared with RA controls, hyperoxia decreased RAC (6.1 ± 0.4 vs. 11.3 ± 0.4, P <0.0001), increased MLI (59.2 ± 1.8 vs. 44.0 ± 0.8, P <0.0001), decreased nodal point density (447 ± 14 vs. 503 ± 12, P <0.0004), and decreased vessel density (11.7 ± 0.3 vs. 18.9 ± 0.3, P <0.001), which persisted despite RA recovery. Compared with hyperoxic controls, rhVEGF treatment after hyperoxia increased RAC (11.8 ± 0.5, P <0.0001), decreased MLI (42.2 ± 1.2, P <0.0001), increased nodal point density (502 ± 7, P <0.0005), and increased vessel density (23.2 ± 0.4, P <0.001). Exposure of neonatal rats to hyperoxia impairs alveolarization and vessel density, which persists despite RA recovery. rhVEGF treatment during recovery enhanced vessel growth and alveolarization. We speculate that lung structure abnormalities after hyperoxia may be partly due to impaired VEGF signaling.

KW - Angiogenesis

KW - Bronchopulmonary dysplasia

KW - Lung development

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=25444484419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444484419&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00336.2004

DO - 10.1152/ajplung.00336.2004

M3 - Article

C2 - 15908474

AN - SCOPUS:25444484419

VL - 289

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1857

IS - 4 33-4

ER -